The Use of Deep Learning in RNA Therapeutic Development
ACS Nano · 2026-06-23 · 20 (24) · 17163-17177
DOI: 10.1021/acsnano.6c02090 ↗At a glance
Übersichtsarbeit in ACS Nano, published online on 2026-06-10. Written by Deepak A Subramanian and 7 co-authors. Institution: Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States. Major MEDLINE topics: Deep Learning, RNA, Genetic Therapy. Cited 1 times so far (Crossref); 183 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, Cystic Fibrosis Foundation, Sanofi.
Abstract (original language)
Ribonucleic acid (RNA)-based therapeutics have emerged as promising methods of disease treatment due to their ability to target the human genome and influence protein production, their versatility, and their relative lack of toxicity compared to other gene therapies. However, the RNA therapeutic design space is extremely large, encompassing multiple variables, including codon identities, secondary structure, and design of specific regions. RNA therapeutic optimization is difficult due to the impracticality of exploring such a vast design space experimentally. To address this limitation, deep learning methods have been employed to optimize RNA therapeutic development. In this review, we examine the application of deep learning models across three key aspects of RNA therapeutic development (RNA structure prediction, CRISPR activity, and RNA delivery), highlighting major contributions in these fields and analyzing how deep learning model architectures could affect model performance. We then discuss challenges associated with using deep learning for RNA therapeutics, such as computational and data limitations. Finally, we offer perspectives on areas for future exploration, such as emerging model architectures and methods of integration with more advanced high-throughput screening techniques. Ultimately, this review provides an overview of how deep learning is used in RNA therapeutic development and how it can evolve in the future.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
- Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
- College of Computing and Data Science, Nanyang Technological University, Singapore 639798, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore.
ORCID profiles: Deepak A Subramanian, Daniel Reker, Daniel G Anderson, Robert Langer, Giovanni Traverso
Funding
- NHLBI NIH HHS
- Cystic Fibrosis Foundation
- Sanofi
- Brigham and Women's Hospital
- Duke University
- Harvard Medical School
- Massachusetts Institute of Technology
- Advanced Research Projects Agency for Health
Cite
APA
Subramanian, D. A., Yao, S. L., Chan, A., Witten, J., Reker, D., Anderson, D. G., Langer, R., & Traverso, G. (2026). The Use of Deep Learning in RNA Therapeutic Development. ACS Nano, 20(24), 17163-17177. https://doi.org/10.1021/acsnano.6c02090
Vancouver
Subramanian DA, Yao SL, Chan A, Witten J, Reker D, Anderson DG, et al. The Use of Deep Learning in RNA Therapeutic Development. ACS Nano. 2026;20(24):17163-17177. doi:10.1021/acsnano.6c02090
BibTeX
@article{Subramanian2026,
author = {Subramanian, Deepak A and Yao, Sophia L and Chan, Alvin and Witten, Jacob and Reker, Daniel and Anderson, Daniel G and Langer, Robert and Traverso, Giovanni},
title = {The Use of Deep Learning in RNA Therapeutic Development},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {24},
pages = {17163--17177},
doi = {10.1021/acsnano.6c02090}
}
EUVIMED